The administration of U.S. President Donald Trump has said it will eliminate a federal subsidy program that has helped hold down rates for Medicare Part D prescription drug plans, in a move that could hike monthly costs for millions of American seniors starting in 2027. The program, designed to “stabilize” the Medicare prescription medication market, is set to expire at the end of 2026, and it won’t be extended.
The subsidy plan was meant to protect insurers from the growing expense of prescription drugs after amendments were implemented under the Inflation Reduction Act. This year, it has offered an anticipated $3.6 billion in support to help slow premium increases for beneficiaries enrolled in stand-alone Medicare Part D medication plans. Some 25 million Americans now have prescription drug coverage as a result of these policies.
Officials at the Centers for Medicare & Medicaid Services (CMS) stated the interim program had achieved its goal of stabilising the market and maintained that insurers now have enough experience to price their plans without more government help. CMS Administrator Dr. Mehmet Oz said most beneficiaries are likely to receive premium hikes of less than $10 per month, and some may see little or no increase depending on the plan they choose.
But independent researchers and health care professionals caution that the elimination of the subsidy could lead to much higher prices for many seniors. The agency forecasts that around 45% of Part D enrollees might face monthly premium hikes between $11 and $20 when new rates take effect in 2027, while others may be able to lower expenses by moving to other plans during the yearly enrolment period.
Many consumer organisations have criticised the move, saying that many older Americans are already dealing with increased costs for health care and prescription medicine. They worry that higher premiums could prompt more beneficiaries to join Medicare Advantage plans, which generally include prescriptions but may have more limited provider networks and different coverage regulations.
The administration said additional protections implemented under the Inflation Reduction Act remain in place, including the yearly ceiling on out-of-pocket prescription drug prices. Officials said the revisions would continue to protect beneficiaries once the premium stabilising project finishes. Final premium prices for 2027 are scheduled to be revealed later this year, allowing beneficiaries to evaluate plans before enrolling.
The announcement comes as healthcare spending continues to be a key political issue in the United States. The administration believes removing the subsidy is a step toward a more competitive insurance market, but opponents warn it might put more of the financial burden onto elderly Americans living on fixed incomes. The effects of the proposal will be more evident when insurers announce their 2027 premiums during the October enrolment period.
About the Author
